Anne Orholm Nielsen

Anne Orholm Nielsen

Auto-generated profile, based on publicly available information

Anne Orholm Nielsen

Zealand University Hospital

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2023 in Chest
Verified
Journal Article
Open access
Kristoffer Mazanti ColdKristoffer Mazanti Cold
Kristoffer Mazanti Cold
SXSujun Xie
Sujun Xie
ANAnne Orholm Nielsen
Anne Orholm Nielsen
PCPaul Frost Clementsen
Paul Frost Clementsen
LKLars Konge
Lars Konge
Navigating through the bronchial tree and visualizing all bronchial segments is the initial step toward learning flexible bronchoscopy. A novel bronchial segment identification system based on artificial intelligence (AI) has been developed to help guide trainees toward more effective training. Does feedback from an AI-based automatic bronchial segment identification system improve novice bronchoscopists' end-of-training performance? The study was conducted as a randomized controlled trial in a standardized simulated setting. Novices without former bronchoscopy experience practiced on a mannequin. The feedback group (FG, n = 10) received feedback from the AI, and the control group (CG, n = 10) trained according to written instructions. Each participant decided when to end training and proceed to performing a full bronchoscopy without any aids. The FG performed significantly better on all three outcome measures (median difference, P-value): Diagnostic Completeness (3.5 segments, P<.001), Structured Progress (13.5 correct progressions, P<.001), and Procedure Time (-214 seconds, P=.002). Training guided by this novel AI makes novices perform more complete, more systematic, and faster bronchoscopies. Future studies should examine its use in a clinical setting and its effects on more advanced learners.

29 May 2025 in European Clinical Respiratory Journal
Verified
Journal Article
Open access
ANAnne Orholm Nielsen
Anne Orholm Nielsen
KRKirsten Brændholt Rasmussen
Kirsten Brændholt Rasmussen
FTFrederikke Bay Toft
Frederikke Bay Toft
HNHenning Bay Nielsen
Henning Bay Nielsen
THThomas Hildebrandt
Thomas Hildebrandt
RBRikke Borg
Rikke Borg
Impaired lung function and fibrotic scarring of the lungs following severe COVID-19 infection are well-known manifestations. However, the risk factors and predisposing factors are still unknown. This study explored whether serological biomarkers for collagen synthesis associate with impaired lung function and fibrotic scarring after COVID-19 infection. In a prospective, observational cohort study involving patients hospitalized with COVID-19 requiring intensive care from June 2020 to December 2021, patients were followed up at 1, 3, 6, and 12 months after discharge. Lung function, diffusion capacity, and a panel of serological biomarkers for collagen-based fibrogenesis (PRO-C3, PRO-C6, and PRO-FIB) were measured. Additionally, a high-resolution CT scan of the lungs was performed at 3 and 12 months. Thirty-four patients were included in the study. Twenty-seven (80%) were men (mean age 61 years). Most patients were former or active smokers (56%), while 44% were never smokers. Levels of both PRO-C3, PRO-C6, and PRO-FIB were higher 3 months after discharge compared to the normal range. The highest levels were measured 1 month after discharge, with PRO-C3 23.2 ng/ml, PRO-C6 15.9 ng/ml, and PRO-FIB 29.3 ng/ml. The levels of PRO-C3 declined up to 6 months after discharge and were hereafter stabilized, whereas the levels of PRO-C6 declined for the entire follow up period. Lung function improved during the first 6 months and then stabilized. Comparing lung function with PRO-C3 and PRO-C6 showed a positive correlation with lung function improving, while levels of the biomarkers declined. However, only PRO-C3 was found to be significantly associated with improvement in lung function 1 month after discharge. This study found that PRO-C3 and PRO-C6 are associated with changes in lung function after severe COVID-19 infection. High levels of both PRO-C6 and PRO-C3 were found up to 6 months after discharge in patients with impaired lung function, however, the values declined towards reference levels after 12 months.